EyePoint, Inc.
$15.07
▲
2.92%
2026-04-21 06:46:01
eyepoint.bio
NGM: EYPT
Explore EyePoint, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.26 B
Current Price
$15.07
52W High / Low
$19.11 / $5.3
Stock P/E
—
Book Value
$3.7
Dividend Yield
—
ROCE
-74.45%
ROE
-72.19%
Face Value
—
EPS
$-3.17
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
214
Beta
1.91
Debt / Equity
46.82
Current Ratio
8.88
Quick Ratio
8.83
Forward P/E
-5.17
Price / Sales
37.74
Enterprise Value
$1.32 B
EV / EBITDA
-5.47
EV / Revenue
42.06
Rating
None
Target Price
$37.42
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | ProQR Therapeutics N.V. | $1.84 | — | $206.51 M | — | -54.09% | -61.17% | $3.1 / $1.1 | $0.54 |
| 2. | Rigel Pharmaceuticals, Inc. | $32.49 | 1.65 | $604.16 M | — | 30.28% | 1.86% | $52.24 / $16.11 | $21.38 |
| 3. | INmune Bio Inc. | $1.49 | — | $39.61 M | — | -128.97% | -1.65% | $11.64 / $1.09 | $0.89 |
| 4. | Day One Biopharmaceuticals, Inc. | $21.48 | — | $2.22 B | — | -28.56% | -22.74% | $21.49 / $5.63 | $4.28 |
| 5. | NeuroSense Therapeutics Ltd. | $0.71 | — | $25.1 M | — | -383.35% | -21.75% | $2.6 / $0.63 | $-0.05 |
| 6. | Immunome, Inc. | $24.25 | — | $2.79 B | — | -35.12% | -52.09% | $27.65 / $6.96 | $5.61 |
| 7. | Vor Biopharma Inc. | $15.71 | — | $810.38 M | — | -84.67% | 2057.65% | $65.8 / $2.62 | $-8.1 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0.62 M | 0.97 M | 5.33 M | 24.45 M | 11.59 M | — |
| Operating Profit | -70.34 M | -62.02 M | -62.23 M | -48.84 M | -45.24 M | — |
| Net Profit | -67.61 M | -59.73 M | -59.43 M | -45.2 M | -41.4 M | — |
| EPS in Rs | -0.81 | -0.72 | -0.71 | -0.54 | -0.5 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 31.37 M | 43.27 M | 46.02 M | 41.4 M |
| Operating Profit | -243.43 M | -145.85 M | -75.07 M | -78.94 M |
| Net Profit | -231.96 M | -130.87 M | -70.8 M | -102.25 M |
| EPS in Rs | -2.78 | -1.57 | -0.85 | -1.23 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 364 M | 418.46 M | 355.18 M | 180.36 M |
| Total Liabilities | 57.88 M | 81.96 M | 88.86 M | 83.99 M |
| Equity | 306.11 M | 336.5 M | 266.32 M | 96.37 M |
| Current Assets | 328.65 M | 383.31 M | 344.8 M | 172.81 M |
| Current Liabilities | 37.02 M | 49.05 M | 63.26 M | 34.54 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -240.11 M | -126.23 M | 1.88 M | -65 M |
| Investing CF | 68.58 M | -219.35 M | -3.31 M | -17.27 M |
| Financing CF | 173.65 M | 164.02 M | 187.07 M | -0.69 M |
| Free CF | -243.39 M | -130.28 M | -1.61 M | -67.16 M |
| Capex | -3.28 M | -4.05 M | -3.48 M | -2.15 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -5.97% | 11.14% | — | — |
| Earnings Growth % | -84.86% | 30.77% | — | — |
| Profit Margin % | -302.43% | -153.84% | -246.97% | — |
| Operating Margin % | -337.06% | -163.13% | -190.65% | — |
| Gross Margin % | 91.42% | 89.93% | 79.89% | — |
| EBITDA Margin % | -298.63% | -149.94% | -233.36% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.